Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 5/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791879 | 0.77 | ADORA3 (0.40) | ADORA3ADORA2ASOSTPDE9ACYP17A1 | |
| SCHEMBL3785205 | 0.75 | CYP11B2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL27955255 | 0.73 | ADORA3 (0.34) | ADORA3ADORA2APDE9ACYP17A1ARG1 | |
| SCHEMBL3777796 | 0.70 | CYP17A1 (0.41) | CYP17A1 | |
| SCHEMBL17014632 | 0.68 | FLT3 (0.37) | ADORA3ADORA2ACYP17A1SIRT3TDP1 | |
| SCHEMBL17169564 | 0.68 | FLT3 (0.37) | ADORA3ADORA2ACYP17A1SIRT3TDP1 | |
| SCHEMBL27955253 | 0.68 | ADORA3 (0.37) | ADORA3ADORA2APDE9ACYP17A1ARG1 | |
| SCHEMBL14991823 | 0.65 | CYP11B1 (0.65) | — | |
| SCHEMBL25890536 | 0.65 | PDE9A (0.34) | SOSTPDE9AARG1ARG2SIRT3 | |
| SCHEMBL18949756 | 0.64 | MAPT (0.54) | ARG1ARG2CHRM1SIRT3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | ADORA3 1612/4885ADORA2A 4346/4885SOST 4335/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | ADORA3 1612/4885ADORA2A 4346/4885SOST 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.